Johnson & Johnson is advancing nipocalimab, an FcRn-blocking antibody that reduces pathogenic IgG, into a 52-week Phase III trial (GARDENIA) for adults with moderate-to-severe SLE after positive Phase II JASMINE data. JASMINE showed nearly 40% of patients on nipocalimab 15 mg/kg achieved LLDAS at week 52 versus ~20% on placebo. The antibody demonstrated a consistent safety profile, is already approved in the EU for gMG, and is being explored across multiple autoantibody-driven indications.
J&J Advances Nipocalimab Into Phase III GARDENIA After Positive Phase II JASMINE Results
J&J EMEA Immunology therapeutic area head Mark Graham. Credit: Johnson & Johnson.
Johnson & Johnson is progressing nipocalimab — an FcRn-blocking antibody designed to reduce pathogenic IgG autoantibodies — into a 52-week Phase III trial (GARDENIA) for adults with moderate-to-severe systemic lupus erythematosus (SLE), following encouraging data from the Phase II JASMINE study.
Phase II JASMINE Findings
In the Phase II JASMINE trial, nipocalimab 15 mg/kg plus background therapy produced clinically meaningful improvements versus placebo. Notably, almost 40% of treated patients reached Lupus Low Disease Activity State (LLDAS) at week 52 compared with about 20% on placebo. LLDAS is an important treat-to-target measure linked to better long-term outcomes and reduced risk of organ damage.
How Nipocalimab Works
Nipocalimab binds the neonatal Fc receptor (FcRn) with high affinity and blocks its function, leading to reduced circulating IgG antibodies, including pathogenic autoantibodies implicated in SLE. The JASMINE study is the first proof-of-concept for an FcRn blocker in SLE and helps clarify FcRn's role in autoantibody-driven disease.
Phase III GARDENIA Trial
The ongoing Phase III GARDENIA study will evaluate nipocalimab over 52 weeks, measuring endpoints such as the SLE Responder Index 4 (SRI-4) and LLDAS in adults with moderate-to-severe SLE. J&J has indicated it will share topline and subsequent data as the study progresses.
Safety And Regulatory Context
Nipocalimab's safety profile in JASMINE was consistent with prior studies and showed no new safety signals. The antibody is already approved in the European Union as an add-on therapy for generalized myasthenia gravis (gMG) in adults and adolescents aged 12 and older who are anti-AChR or anti-MuSK antibody positive — underscoring the clinical relevance of targeting the autoantibody pathway.
Broader Development Plans
J&J is exploring nipocalimab across multiple autoantibody-driven segments, including rare neurologic and hematologic disorders, maternal–fetal alloimmune conditions, and rheumatologic indications. The company says these programs target areas of high unmet medical need where pathogenic IgG plays a central role.
Mark Graham, Head of Immunology Therapeutics for J&J EMEA: “We are committed to addressing unmet needs in SLE by targeting disease-driving pathways such as pathogenic IgG autoantibodies. The JASMINE data supported moving forward into Phase III, and we look forward to sharing additional results from GARDENIA.”
Originally published by Clinical Trials Arena, a GlobalData brand. This article summarizes J&J statements about nipocalimab’s clinical development and trial objectives.
Help us improve.
